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(1)	 To	 advance	 cartilage	 cell	 therapy	 by	 improving	 the	 expansion	 and	
chondrogenic	capacity	of	cultured	human	chondrocytes.	
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CD49c	 80	µl	 C3	IL1	 IgG1	 Phycoerythrin		








































































































































































































































































ALK1	 Activin	A	receptor	type	II-like	1	 -	74	(NM_000020)	 94	

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































44	 820,000	 392	 2091.84	
47	 422,222	 96	 4398.15	
55	 750,000	 456	 1644.74	
59	 640,000	 212	 3018.87	
62	 580,000	 409	 1418.09	
Knees	-	
47	 3,720,000	 1950	 1907.69	
55	 1,890,000	 1200	 1575	
61	 2,330,000	 2728	 854.11	
64	 625,000	 472	 1323.59	


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Female	 Male	 Age	range	 Mean	age	 Pre-
operative	
Post-operative	




































































































































































































































































































































































































































































OsAS	 0.928	 0.891	 0.952	
MOxFQ	Pain	 0.757	 0.652	 0.834	
MOxFQ	Symptoms	 0.795	 0.704	 0.861	




























































































































0.810	 0.850	 0.828	 0.780	
95%		
Lower	CI	
0.729	 0.802	 0.770	 0.723	
95%	Upper	
CI	




























































































































































standard	 used	 in	 research;	 FBS.	 Stemulate™,	 a	 commercially	 available	 human	
platelet	 lysate,	 has	 been	 previously	 utilised	 to	 improve	 MSC	 expansion.	 With	
freshly	isolated	human	chondrocytes,	we	reported	an	increase	in	proliferation	in	
monolayer	culture,	however,	despite	a	28-day	three-dimensional	culture	period	
the	 chondrocytes	 did	 not	 recover	 their	 chondrogenic	 capacity	 to	 the	 extent	 of	
those	cells	cultured	in	the	presence	of	FBS.	Although	this	research,	which	has	been	
published	 (Sykes	 et	 al	 2018;	 page	 238),	 determined	 that	 Stemulate™	was	 less	
effective	than	FBS,	it	might	still	have	some	place	in	the	ACI	protocol.	We	would	











chondrocytes	 sourced	 from	 ankle	 cartilage	 could	 be	 of	 ‘better	 quality’	 than	
chondrocytes	sourced	from	knee	cartilage.	Our	research	showed	that	ankle	and	
knee	 chondrocytes	 differed	 metabolically	 and	 histologically,	 with	 ankle	
chondrocytes	 demonstrating	 a	 slower	 growth	 in	monolayer	 culture	 but	 higher	
chondrogenic	 capacity	 compared	 to	 knee	 chondrocytes,	 irrespective	 of	 the	









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	 	  
 
Page 1 of 8 
Miss Jessica Sykes 
Institute for Science & Technology in Medicine, 
University of Keele, 
Arthritis Research Centre, Robert Jones & Agnes Hunt 






10 May 2017 
 
Dear Miss Sykes,     
 
 
Study title: A study to develop a new and validated questionnaire to 
assess the outcomes for foot and ankle surgical treatments 
at The Robert Jones & Agnes Hunt (RJAH) Orthopaedic NHS 
Hospital. 
IRAS project ID: 216460  
Protocol number: RG-0048-16-ISTM 
REC reference: 17/NW/0063   
Sponsor Keele University 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the 
basis described in the application form, protocol, supporting documentation and any clarifications 
noted in this letter.  
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS organisations in England.  
 
Appendix B provides important information for sponsors and participating NHS organisations in 
England for arranging and confirming capacity and capability. Please read Appendix B carefully, in 
particular the following sections: 
x Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities 
x Confirmation of capacity and capability - this confirms whether or not each type of participating 
NHS organisation in England is expected to give formal confirmation of capacity and capability. 
Where formal confirmation is not expected, the section also provides details on the time limit 
given to participating organisations to opt out of the study, or request additional time, before 
their participation is assumed. 
x Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) - this provides detail on the form of agreement to be used in the study to confirm 
capacity and capability, where applicable. 





















Severe	 	 moderate	 	 mild	 	 	 none	
	
2. During	the	last	week,	what	level	of	pain	have	you	experienced	from	yourankle	at	night?	
Severe	 	 moderate	 	 mild	 	 	 none	
	
3. During	the	last	week,	how	often	did	you	experience	pain	from	your	ankle?	




















































Unable		 	 extreme	 moderate	 	 mild	 	 none		
	
2. Sitting	for	a	long	period	of	time	(for	example:	1	hour)	
	Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
3. Walking	for	a	short	period	of	time	(for	example:	1-15	minutes)	
		Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
4. Walking	a	long	distance	(for	example:	greater	than	1	kilometre)	
		Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
5. Raising	your	heel	to	stand	on	your	tip	toes	
		Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
6. Climbing	up	and	down	stairs	
	Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
7. Getting	in	and	out	of	the	car	or	public	transportation	
	Unable		 	 extreme	 moderate	 	 mild	 	 none		
	
8. Getting	in	and	out	of	the	shower	or	bath		
	Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
9. Performing	light	daily	household	activities	(for	example:	cooking)	






Unable		 	 extreme	 moderate	 	 mild	 	 none	
	
11. Sleeping	








		Unable		 	 extreme	 moderate	 	 mild	 	 none		
	
14. To	what	extent	did	your	ankle	problem	affect	your	daily	life?	


















































Severe	 	 Moderate	 	 Mild	 	 None	
	
2. During	the	last	week,	how	often	did	you	experience	pain	from	your	ankle?	








Always	 	 Often	 	 Rarely	 	 Never	
	
4. To	what	extent	did	your	ankle	problem	affect	your	daily	life?	























Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
9. Sitting	for	a	long	period	of	time	(for	example:	1	hour)	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
10. Walking	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
11. Climbing	up	and	down	stairs	
Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
12. Getting	in	and	out	of	the	car	or	public	transportation	




Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
	
14. Performing	daily	household	activities	(for	example:	cooking,	scrubbing	floors)	








Unable		 	 Extreme	 					Moderate	 Mild	 	 None		
			
17. To	what	extent	did	your	ankle	affect	your	emotional	wellbeing?	
			Never	 	 Rarely	 				Sometimes	 Often	 	 Always	
	
18. How	often	did	you	walk	with	a	limp	due	to	your	ankle	problem?	






Yes	–	please	give	details	below	 	 	 	 No	
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